CUBRC works with drug, diagnostic, medical device and vaccine developers to secure US Government funding for activities spanning the development pipeline including lead identification and optimization, early preclinical development, IND enabling studies, and clinical studies. CUBRC operates as a systems integrator and prime contractor applying our deep expertise managing complex government-funded science and technology programs. This reduces risk for our partners and for the government, which increases the likelihood of award and successful execution of contracts aimed at the development of therapeutics and vaccines for use against traditional public health diseases as well as for indications associated with the use of biological, chemical or radiological weapons.
In addition to working as a systems integrator on pharmaceutical development programs, CUBRC supports our partners by providing BSL-2 and BSL-laboratory based research, development, testing and evaluation (RDT&E). In particular, we support drug and device development by assessing the efficacy of therapies in our laboratories using a variety of in vitro assays with multiple public health and biological threat agents.
Our goal for this webinar is to familiarize the MTEC community with CUBRC and our capabilities and offerings in medical countermeasure development and biological defense RDT&E.
Speaker:
Katie Edwards, Ph.D., Director, Biological and Medical Sciences, CUBRC, Inc.
